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Abstract
Background—Whole-body hypothermia reduced the frequency of death or moderate/severe
disabilities in neonates with hypoxic-ischemic encephalopathy in a randomized, controlled
multicenter trial.
Objective—Our goal was to evaluate outcomes of safety and effectiveness of hypothermia in infants
up to 18 to 22 months of age.
Design/Methods—A priori outcomes were evaluated between hypothermia (n = 102) and control
(n = 106) groups.
Results—Encephalopathy attributable to causes other than hypoxia-ischemia at birth was not noted.
Inotropic support (hypothermia, 59% of infants; control, 56% of infants) was similar during the 72-
hour study intervention period in both groups. Need for blood transfusions (hypothermia, 24%;
control, 24%), platelet transfusions (hypothermia, 20%; control, 12%), and volume expanders
(hypothermia, 54%; control, 49%) was similar in the 2 groups. Among infants with persistent
pulmonary hypertension (hypothermia, 25%; control, 22%), nitric-oxide use (hypothermia, 68%;
control, 57%) and placement on extracorporeal membrane oxygenation (hypothermia, 4%; control,
9%) was similar between the 2 groups. Non–central nervous system organ dysfunctions occurred
with similar frequency in the hypothermia (74%) and control (73%) groups. Rehospitalization
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What's Known on This Subject: Term infants with moderate or severe encephalopathy caused by acute perinatal asphyxia are at risk
for death and disability in childhood. Hypothermia, either whole-body cooling or selective head cooling, has been found to provide
neuroprotection.
What This Study Adds: There are possible adverse effects of cooling in neonates. For the NICHD trial of whole-body cooling for
neonatal HIE, we report on outcomes of safety and effectiveness during cooling and at up to 18 months of age.
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occurred among 27% of the infants in the hypothermia group and 42% of infants in the control group.
At 18 months, the hypothermia group had 24 deaths, 19 severe disabilities, and 2 moderate
disabilities, whereas the control group had 38 deaths, 25 severe disabilities, and 1 moderate disability.
Growth parameters were similar between survivors. No adverse outcomes were noted among infants
receiving hypothermia with transient reduction of temperature below a target of 33.5°C at initiation
of cooling. There was a trend in reduction of frequency of all outcomes in the hypothermia group
compared with the control group in both moderate and severe encephalopathy categories.
Conclusions—Although not powered to test these secondary outcomes, whole-body hypothermia
in infants with encephalopathy was safe and was associated with a consistent trend for decreasing
frequency of each of the components of disability.
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Among term infants, hypoxic-ischemic encephalopathy (HIE) caused by acute perinatal
asphyxia remains an important cause of neurodevelopmental deficits in childhood.1,2
Currently, there is increasing evidence that mild or moderate brain hypothermia reduces brain
injury caused by hypoxia and ischemia.3–7 We have demonstrated that whole-body
hypothermia reduces the risk of death or disability in infants with moderate or severe HIE.6
However, enthusiasm regarding the beneficial effects of hypothermia has been tempered by
concerns of safety. These concerns have focused on potential complications involving
coagulation and immunologic defects, cardiovascular and pulmonary compromise, metabolic
adverse effects, and hematologic effects.8–13
In the Eunice Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) Neonatal Research Network's randomized, controlled trial of whole-body cooling
for neonatal HIE, very few adverse events were noted during the 72-hour intervention period.
6 We noted 2 cases of cardiac arrhythmia (1 case in the hypothermia group and 1 in the control
group), 2 cases of persistent acidosis (in the hypothermia group), 5 cases of bleeding (3 infants
in the hypothermia group and 2 infants in the control group), skin changes (in 4 cooled infants),
and 24 deaths (13 in the hypothermia group and 11 in the control group). The objective of the
present study was to report other secondary outcomes of safety and effectiveness of whole-
body cooling in the trial participants up to 18 to 22 months of age. The trial was not designed
to assess harm or adverse events; we acknowledge the limited power to assess adverse events
that are infrequent.
Patients and Methods
Data from the NICHD Neonatal Research Network whole-body hypothermia trial were used
for this analysis.6 Neonates with either moderate or severe encephalopathy based on a modified
Sarnat scoring14 were randomly assigned to whole-body cooling or usual care. Total-body
cooling to a temperature of 33.5°C was maintained for 72 hours in the cooled group followed
by rewarming at 0.5°C every hour for 6 hours. The primary outcome of the study was either
death or moderate or severe disability at 18 to 22 months of age. Severe disability was defined
as a Mental Developmental Index (MDI) on the Bayley Scales of Infant Development II15 of
<70 or Gross Motor Functional Classification System (GMFCS)16 rating of 3 to 5 or bilateral
blindness or deafness requiring amplification. Moderate disability included an MDI of 70 to
84 and a GMFCS level of 2, a hearing deficit without amplification, or a seizure disorder
requiring anticonvulsive therapy at 18 months of age.
To monitor for potential adverse effects of hypothermia, data collected during the 72-hour
intervention and rewarming period included blood pressure support and transfusion needs,10
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as well as effects of anticonvulsant and analgesic/sedation medications12,13 on target
temperature. In addition, changes in oxygen requirements among those infants diagnosed with
persistent pulmonary hypertension of the newborn (PPHN) were collected during the study
intervention and rewarming period.
During the hospital stay, our evaluation also included a detailed review of medical charts to
identify other potential causes of encephalopathy aside from hypoxia-ischemia that have been
noted by other investigators, including infectious, metabolic, and neuromuscular causes or
major congenital anomalies.17,18 In addition, we documented the frequency of multiorgan
injury other than the central nervous system (CNS).2,17,19 Pulmonary involvement included
meconium-aspiration syndrome, PPHN (including use of inhaled nitric oxide and placement
on extracorporeal membrane oxygenation [ECMO]), chronic lung disease, and/or pulmonary
hemorrhage. Cardiac involvement included cardiomegaly, cardiac failure and cardiac
dysfunction indicated by echocardiography, cardiac ischemia indicated by
electrocardiography, or elevated enzyme levels, hypotension, hypertension, and/or arrhythmia.
Renal involvement included oliguria, anuria, and/or dialysis. Gastrointestinal involvement
included hepatic dysfunction or necrotizing enterocolitis. Infectious diseases included
bloodstream infection, meningitis, or encephalitis. Hematologic dysfunction included
disseminated intravascular coagulopathy, and metabolic dysfunction included hypoglycemia,
hypocalcemia, and/or hypomagnesemia.
After NICU discharge, data were collected on hospitalizations, growth parameters, and
neurologic and developmental outcome (as defined above) at 18 to 22 months of age.
Microcephaly was defined as a head circumference below the 10 percentile.
Dichotomous data were compared by using Fisher's exact test, and continuous data were
analyzed by linear regression analysis. Relative risks and 95% confidence intervals were
obtained by using the Mantel-Haenszel test, with adjustments accounting for center differences.
A significance level of <.05 was used for comparisons between the 2 treatment groups.
Results
Hospital Stay in the NICU
The diagnosis of encephalopathy at enrollment was confirmed by review of status at death or
NICU discharge for all study participants. None of the study infants were diagnosed to have
malformations or metabolic or neuromuscular disorders as a cause of encephalopathy despite
routine screening with cranial sonography and MRI and intensive assessments before NICU
discharge.
In the hypothermia group, the esophageal temperature was noted to be transiently reduced with
the initiation of cooling to below the target temperature of 33.5°C.6 The mean time to initially
surpass 33.5°C was 0.9 ± 0.5 hours (range: 0.25–3.50 hours). The mean maximum overshoot
below the target temperature was −1.4°C ± 0.6°C (range: 0.0°C−4.1°C). The mean time to
maximum overshoot below the target temperature was 1.3 ± 1.0 hours (range: 0.25–8.00 hours).
The mean time to equilibration after overshoot (defined as within 0.1°C of target temperature)
was 1.9 ± 3.6 hours (range: 0.0–21.0 hours) after initiation of cooling. We noted some
unexpected findings: (1) 1 infant never achieved equilibration, and (2) there were 40
temperatures recorded to be <32.0°C after the initial overshoot. There were 27 infants with
temperatures of <32.0°C after the initial overshoot and 10 infants who had temperatures of
<32.0°C after equilibration.
During the study intervention period, among the infants who were cooled, there were no
significant differences in the median or first- and third-quartile esophageal temperatures among
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infants who received anticonvulsants and those who did not receive these medications. At 24,
48, and 72 hours, the mean esophageal temperatures were, respectively, 33.4°C, 33.3°C, and
33.4°C among those who received anticonvulsants and 33.3°C, 33.4°C, and 33.3°C among
those who did not receive these medications. Similar esophageal temperatures were recorded
at 24, 48, and 72 hours among infants who received sedatives and those who did not receive
sedatives. In the hypothermia group at the end of the 72-hour intervention of cooling, the mean
esophageal temperature was 33.4°C ± 0.4°C. At 76 hours of study intervention, during the
rewarming phase, the mean esophageal temperature was 35.3°C ± 0.6°C. At the end of the
rewarming phase, at 78 hours of study intervention, the mean esophageal temperature was
35.9°C ± 0.8°C. Because esophageal temperatures were not recorded every 4 hours after 78
hours, information is lacking as to when infants in the hypothermia group reached “normal”
esophageal temperatures.
Events that occurred and therapies that were provided during the NICU stay are noted in Table
1. The use of inotropic agents, volume expanders, blood transfusions, or platelet transfusions
during the study intervention period was comparable among infants in the hypothermia and
control groups. The platelet count at 72 hours of study intervention was a median of 132 in the
hypothermia group (quartile 1 to 3: 77–194) and 129 in the control group (quartile 1 to 3: 78–
195). The minimum platelet count during the 72-hour period was a median of 139 (quartile 1
to 3: 62–211) and 156 (quartile 1 to 3: 87–202) in the hypothermia and control groups,
respectively. The number of infants with clinical seizures at baseline and at 48 and 72 hours
of study intervention were similar in the hypothermia group compared with the control group
(Table 1). At 24 hours of study intervention, fewer infants in the hypothermia group had
seizures as compared with those in the control group.
The number of infants who had any of the 7 organ systems (pulmonary, cardiac, renal,
gastrointestinal, infectious, hematologic, and metabolic) involved, in addition to the CNS, was
76 infants in the hypothermia group and 77 in the control group. One-organ-system
involvement, in addition to the CNS, was noted among 25 infants in the hypothermia group
and 36 in the control group; 2-organ-system involvement was noted among 23 in the
hypothermia group and 13 in the control group; and 3-organ-system involvement was noted
among 14 in the hypothermia group and 15 in the control group. Seven infants in the
hypothermia group had 4 systems involved compared with 10 infants in the control group, and
>4-system involvement occurred in 7 infants in the hypothermia group compared with 3 in the
control group.
The number of infants diagnosed with PPHN was 25 in the hypothermia group and 23 in the
control group (Table 1). The mean fraction of inspired oxygen (FiO2) requirement among
infants with PPHN during the 72-hour intervention period was similar between groups; at 24,
48, and 72 hours, the requirement was, respectively, 0.97, 0.97, and 0.94 in the hypothermia
group and 0.90, 0.65, and 0.53 in the control group. The number of infants who received inhaled
nitric oxide or who were placed on ECMO was also comparable between the 2 groups.
Nineteen infants had major surgery before NICU discharge; these surgeries included ECMO
cannulation in 1 infant in the hypothermia group and 2 in the control group; other procedures
among the 16 infants are listed in Table 1.
Rehospitalization and Growth Parameters at 18 Months of Age
The number of infants who were rehospitalized was comparable in both the hypothermia and
control groups (Table 2). Growth parameters were also comparable in infants in the
hypothermia and control groups. The number of infants who had microcephaly was 22 (30%)
of 74 in the hypothermia group and 17 (27%) of 62 in the control group (P = .77); microcephaly
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noted was observed only at the 18-month visit, because the growth parameters at birth were in
the normal range.6
Death or Disabilities at 18 Months of Age
The study's primary outcome was death or moderate or severe disabilities at 18 months of age
(Table 3). There were 24 deaths in the hypothermia group and 38 in the control group, and
there were 19 infants in the hypothermia group diagnosed with a severe disability, whereas 25
infants in the control group were noted to have a severe disability. Severe disabilities among
these 44 infants included 34 with an MDI of <70 and at least 1 of the other components of
severe disability, 9 infants with only an MDI of <70, and 1 infant with an MDI of 70 to 84 with
deafness. Only 3 infants had a moderate disability; 2 infants in the hypothermia group (1 infant
with an MDI of 70–84 and hearing impairment with no amplification and the other with an
MDI of 70–84 and a GMFCS level 2) compared with 1 infant in the control group (MDI of
70–84 and seizure disorder at 18 months). Among the 29 infants with quadriplegia, additional
neurologic findings included truncal hypotonia (n = 6), truncal hypotonia with athetosis (2
infants), generalized hypotonia (1 infant), generalized hypertonia (1 infant), athetosis (1 infant),
and dystonia (1 infant).
Relationship of Severity of Encephalopathy at Randomization to Outcome at 18 Months of
Age
Data were missing from the 3 infants in the control group (lost to follow-up) and 1 infant in
the hypothermia group (this infant qualified for study eligibility with seizures at <6 hours of
age but did not have a neurologic examination at randomization) (Table 3). Although the study
was not powered to evaluate death or disability separately among infants designated as having
moderate encephalopathy and severe encephalopathy, there was a consistent trend in the
decrease in frequency of disability in the infants in the hypothermia group compared with those
in the control group.
Association of Variables Evaluated for Safety with Outcome at 18 to 22 Months of Age
Among the infants in the hypothermia group, the mean time to maximum overshoot at the onset
of cooling was not related to the primary outcome (1.2 ± 0.5 hours in infants with the primary
outcome compared with 1.4 ± 1.3 hours among those without the primary outcome [P = .23]).
The mean time to equilibration of target temperature after maximum overshoot also did not
impact outcome (2.3 ± 4.1 vs 1.5 ± 3.2 hours with primary outcomes versus without the primary
outcome, respectively [P = .29]). Last, the outcome of infants in the hypothermia group with
an esophageal temperature recorded below 33.5°C was not related to the primary outcome:
those with the primary outcome spent 45 ± 21 hours below 33.5°C, whereas those without the
primary outcome spent 51 ± 16 hours below 33.5°C (P = not significant).
The presence of non-CNS organ dysfunction during the neonatal course (in addition to HIE)
was related to the primary outcome. The risk varied with the organ system involved: pulmonary
involvement (n = 63) was associated with primary outcome in 65% vs 48% with no pulmonary
involvement (P = .02). Renal involvement (n = 44) was associated with a primary outcome in
68% vs 49% with no renal involvement (P = .03); there was a trend for cardiac involvement
(n = 91) to be associated with the primary outcome in 60% vs 48% with no cardiac involvement
(P = .09). Gastrointestinal, hematologic, or metabolic problems, in addition to HIE, did not
increase the risk of the primary outcome.
Among the outcomes assessed at follow-up, the presence of microcephaly was not associated
with treatment group; however, microcephaly was significantly associated with primary
outcome in both groups. In the hypothermia group, 82% of the infants with microcephaly had
the primary outcome present compared with 6% without microcephaly, whereas in the control
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group, 71% with microcephaly had the primary outcome present compared with 27% without
microcephaly (all P < .01).
Discussion
The data we have presented support the safety of whole-body hypothermia for infants with
moderate and severe HIE when adhering to strict entry criteria and cooling initiated within 6
hours of age at participating centers. A relative risk of < 1.0 was identified for death and each
of the components of severe disability at 18 to 22 months of age. Our data support the safety
of hypothermia during the period of cooling as well as during the NICU hospitalization and
follow-up through 18 to 22 months of age.
We did not find any decrease in platelet counts or increase in bleeding episodes among infants
in our study. Our protocol did not include investigations to evaluate the coagulation profile or
blood viscosity status for all participants. Eicher et al10 noted a low platelet count on each day
of cooling with an increase in platelet count on the fourth day. However, no clinical
manifestations of coagulopathy were found in that study. In the same trial, treatment was used
for hypotension among more infants in the cooled group as compared with the control group.
It should be noted that 77% of the infants who were enrolled in the Eicher et al trial had severe
encephalopathy at the time of enrollment, and 75% of the infants were outborn. In the other 2
larger randomized, controlled trials, the CoolCap study and the NICHD trial, infants with
severe encephalopathy comprised ∼33% of enrolled infants and fewer were outborn compared
with the Eicher et al trial.4,6
The cardiovascular complications associated with hypothermia in adult cooling trials include
pulmonary vasoconstriction, sinus bradycardia, cardiac arrhythmia, and increased blood
viscosity.20–22 All the neonatal cooling studies have documented sinus bradycardia during the
period of cooling without significant cardiovascular effects.4–7,10 A recent study has
documented that in term neonates undergoing hypothermia for HIE, cardiac output and stroke
volume are both lower during the period of hypothermia and slowly increase to baseline during
the rewarming phase.23 Investigators have also noted that the QT interval can be prolonged
with cooling, and hypotension can occur during cooling.24 We have reported previously that
there was no difference between systolic and diastolic blood pressure throughout the period of
study intervention.6 In this study, we observed similar use of inotropic agents, blood
transfusions, and volume expanders during the study period in the 2 groups. The number of
infants who required aggressive therapy for PPHN, including inhaled nitric oxide or ECMO,
was not higher among infants who were cooled as compared with control infants in our study.
In addition, we did not find that administration of anticonvulsant drugs or analgesics/sedatives
produced decreases in temperature during cooling as noted by others.12,13 This lack of
influence of medications on esophageal temperature may be a result of the cooling system that
was servo-controlled and adjusted cooling to maintain a stable temperature.
Hypothermia has profound immunosuppressive and antiinflammatory effects and in adults is
associated with increased risk of infectious complications such as pneumonia and bloodstream
infection.20–22 We did not find an increase in the rate of bloodstream infection among the
infants who were cooled, either during the intervention period or during the entire
hospitalization course.
In this study, we found that fewer infants in the hypothermia group had clinical seizures after
24 hours of study intervention as compared with the control group. We are unable to explain
this finding, which is different from the findings of Eicher et al.10 Video
electroencephalography recording was not a part of the protocol; hence, it is likely that the
incidence of seizures was underestimated. Recent preclinical studies have noted that
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hypothermia delays onset of seizures and reduces seizure incidence and severity, and there
have been no experimental data to suggest that hypothermia increases seizures.25
Conclusions
The safety of whole-body cooling initiated within 6 hours of age to a depth of 33.5°C for 72
hours' duration has been demonstrated. However, the rate of death and disability continues to
be high, even with this safe method of cooling. In the NICHD trial, hypothermia to 33.5°C for
72 hours reduced death and disability of infants with moderate HIE to 32% and severe HIE to
72%. Preclinical data suggest that cooling earlier and to a greater depth may be more effective.
8,26,27 However, the safety of cooling during transport of infants to a referral center has not
been evaluated yet.
At the present time, no pharmacologic agent is ready for clinical trials in neonates with HIE.
28 The method of cooling we have described needs to be improved with no/minimal overshoot
and rapid achievement and stability of the target temperature. The observation of unexplained
transient decreases in esophageal temperature to <32°C during cooling using servo control
emphasizes the need to have trained staff available who are well versed with all potential
technical problems associated with a cooling regimen. It is also apparent that monitoring of
temperatures needs to be continued beyond 6 hours after cessation of cooling and initiation of
rewarming, because it is unclear when normal temperature is achieved. We suggest that clinical
trials in the future be focused on defining the optimal degree and duration of cooling and
rewarming strategies as neuroprotection for neonatal encephalopathy.
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Table 1
Acute Outcome in the NICU
Parameter Hypothermia
(N = 102)
Control Group
(N = 106)
RR (95% CI)
During study intervention, n (%)
 No BP support at any timea 41 (41) 44 (44) 0.91 (0.67–1.24)
 BP support at any of the 4 time points: baseline or 24,
48, or 72 h
58 (59) 55 (56) 1.07 (0.86–1.34)
 BP support throughout 72 h 19 (19) 18 (18) 1.09 (0.60–1.95)
   1 medication at each time point 11 (12) 8 (9) 1.31 (0.55–3.11)
   1 medication at some time points, >1 at other time
points
4 (4) 6 (6) 0.69 (0.21–2.31)
   ≥2 medications at each time point 4 (4) 4 (4) 1.29 (0.31–5.43)
 Volume expanders at any time 55 (54) 52 (49) 1.14 (0.88–1.47)
 Blood transfusion at any time 24 (24) 25 (24) 0.98 (0.59–1.61)
 Platelet transfusion at any time 20 (20) 13 (12) 1.60 (0.82–3.14)
 Seizures, n (%)
   At baseline 44 (43) 51 (48) 0.92 (0.70–1.21)
   At 24 h 19 (20) 34 (34) 0.62 (0.38–0.99)b
   At 48 h 13 (14) 20 (22) 0.67 (0.36–1.27)
   At 72 h 8 (9) 12 (13) 0.78 (0.33–1.82)
During hospitalization
 PPHN, n (%) 25 (25) 23 (22) 1.16 (0.72–1.88)
 Among infants with PPHN, n (%)
   Inhaled nitric oxide 17 (68) 13 (57) 1.37 (0.85–2.21)
   ECMO 1 (4) 2 (9) 0.62 (0.08–4.92)
 Bloodstream infectionc 5 (5) 6 (6)
Surgery
 Gastric fundoplication 1 0
 Gastrostomy 3 6
 Gastric fundoplication and Gastrostomy 0 4
 Tracheostomy, fundoplication and gastrostomy 0 1
 Other 0 1
a
Three hypothermia-group infants and 7 control-group infants had data missing at ≥1 time point.
b
P < .05; the rest were all nonsignificant.
c
Bloodstream infection includes 1 in hypothermia group and 2 in the control group from samples drawn before study enrollment.
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Table 2
Status at 18 Months of Age
Parameter Hypothermia
(N = 78)
Control
(N = 68)
Value
Rehospitalizations, n (%)a
 Any 21 (27) 26 (42) 0.67 (0.42 to 1.07)b
 1 8 (12) 14 (28) 0.48 (0.21 to 1.10)b
 2–3 10 (13) 6 (11) 1.31 (0.52 to 3.29)b
 >3 3 (4) 6 (10) 0.38 (0.09 to 1.58)b
Growth parameters, mean ± SD
 Weight, kgc 11.4 ± 1.8 11.0 ± 2.3 0.31 (−0.37 to 0.98)d
 Height, cmc 81.7 ± 5.9 80.0 ± 10.6 1.73 (−1.10 to 4.56)d
 Head circumference, cme 46.9 ± 5.3 46.7 ± 2.5 0.19 (−1.24 to 1.62)d
a
NICU discharge to follow-up visit. Missing hospitalization data for 6 infants in the control group.
b
Data shown are RRs (95% CIs).
c
Data missing for 2 hypothermia and 6 control group infants.
d
Data shown are the adjusted mean differences.
e
Data missing for 2 hypothermia and 5 control group infants.
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Table 3
Death and Disability at 18 Months
Parameter Hypothermia
(N = 102),
n (%)
Control
(N = 106),
n (%)
RR (95% CI)
Death 24 (24) 38 (37) 0.68 (0.44–1.05)
Severe disability 19 (24) 25 (38) 0.67 (0.41–1.10)
Moderate disability 2 (3) 1 (3) 1.11 (0.14–8.45)
Disabling cerebral palsy 15 (19) 19 (30) 0.68 (0.38–1.22)
 Spastic quadriplegia 14 (93) 15 (79)
 Hemiplegia 1 (7) 1 (5)
 Triplegia 0 (0) 1 (5)
Truncal hypotonia and dystonia 0 1
Generalized hypotonia 0 1
Completely normal 32 (32)a 22 (22) 1.40 (0.88–2.22)
Moderate HIE 69 63
 Death 9 (13) 14 (21) 0.55 (0.25–1.21)
 Disabling CP 8 (14) 10 (21) 0.64 (0.25–1.65)
 MDI of <70 12 (21) 14 (30) 0.74 (0.35–1.55)
 MDI of 70–84 15 (33) 12 (36) 0.87 (0.49–1.54)
 Blindness 3 (5) 5 (11) 0.50 (0.12–2.07)
 Hearing impairment 7 (12) 5 (10) 1.13 (0.37–3.43)
 Deafness 1 (2) 3 (6) 0.24 (0.02–2.54)
 Seizures 9 (15) 10 (21) 0.69 (0.27–1.76)
 Multiple impairments 9 (15) 10 (20) 0.73 (0.29–1.83)
 Completely normal 26 (39) 19 (32) 1.17 (0.73–1.87)
Severe HIE 32 40
 Death 15 (47) 24 (60) 0.80 (0.46–1.40)
 Disabling CP 7 (41) 9 (56) 0.70 (0.33–1.51)
 MDI of <70 7 (41) 10 (67) 0.71 (0.38–1.33)
 MDI of 70–84 2 (20) 1 (20)
 Blindness 2 (13) 4 (25) 0.69 (0.16–2.93)
 Hearing impairment 3 (18) 1 (6) 4.00 (0.36–44.11)
 Deafness 2 (12) 1 (6) 2.00 (0.13–31.98)
 Seizures 4 (24) 4 (29) 0.79 (0.22–2.90)
 Multiple impairments 6 (35) 9 (56) 0.70 (0.33–1.51)
 Completely normal 5 (16) 3 (8) 1.67 (0.43–6.56)
Primary outcome was missing for 3 control infants. MDI was unavailable for 3 hypothermia-group and 6 control-group infants. CP and deafness
information was unavailable for 1 hypothermia-group and 4 control-group infants and blindness information was missing for 3 hypothermia-group
and 5 control-group infants. Multiple impairments include 2 or more of the following: disabling CP, MDI of <70, blindness, or deafness. Completely
normal was defined as MDI and Psychomotor Developmental Index scores of ≥85 with normal neurologic examination and normal hearing and vision.
CP indicates cerebral palsy.
a
One infant in the hypothermia group qualified for study with seizures but was missing a neurologic examination to permit classification of extent of
encephalopathy.
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